In Vivo Effect of Suloctidil as an Antiplatelet Agent

Summary

The relationship between the effects of suloctidil in vivo as an antiplatelet agent and in vitro as a modifier of platelet serotonin (5-HT) parameters was investigated. Suloctidil was found to be effective in reducing platelet aggregates formation in the retired breeder rat as determined using the platelet aggregate ratio method (PAR) with an ED₅₀ of 16.1 mg/kg 24 hours post administration. In contrast to the hypothesis that 5-HT depletion is involved in the anti-aggregatory mechanism of suloctidil, no correlation was found between platelet 5- HT content and this antiplatelet activity. Reduction of platelet 5-HT content required multiple injections of high doses (100 mg/kg/day) of suloctidil. Suloctidil administration for 8 days at 100 mg/kg/day, which lowered platelet 5-HT content by 50%, resulted in no permanent effect on ex vivo platelet 5-HT uptake or thrombin-induced release, nor alteration in the plasma 5-HT level. However, these platelets exhibited a short-lived, significant increase in percent leakage of 5-HT after 30 minutes of incubation. Therefore, suloctidil treatment at high doses may with time result in platelet 5-HT depletion, however this effect is probably not related to the primary anti-aggregatory activity of the drug.

• References

• 1 Burns TS, Saunders RN. 1977; Quantitation of in vivo platelet aggregation by the platelet aggregate ratio method. Thrombosis Research 10: 629
• 2 De Gaetano G, Miragliotta G, Roncucci R, Lansen J, Lambelin G. 1976; Suloctidil: A novel inhibitor of platelet aggregation in human beings. Thrombosis Research 8: 361
• 3 De Gaetano G, Cavenaghi AE. 1977; a Effect of suloctidil on bleeding time and in vivo platelet aggregation in rats. Thrombosis Research 10: 525
• 4 De Gaetano G, Roncaglioni MC, Miragliotta G, Wielosz M, Garattini S. 1977; b In vitro effect of suloctidil on¹⁴C-5-hydroxytryptamine uptake and liberation in rat platelets. Pharmacological Research Communications 9: 315
• 5 Drummond AH, Gordon JL. 1976; Uptake of 5-hydroxytryptamine by rat blood platelets and its inhibition by adenosine 5-diphosphate. British Journal of Pharmacology 56: 417
• 6 Gadd RE A, Clayman S. 1972; A reassessment of the use of modified Tyrode’s solution as a physiological medium for suspension of isolated platelets. Experientia 28: 719
• 7 Gurewich V, Lipinski B. 1976; Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thrombosis Research 9: 101
• 8 Harker LA. 1976; Communication at the IXth world conference, European Society for Microcirculation, Antwerp, July. 6
• 9 Mills DC B, Mcfarlane DE. 1976; Suloctidil: A potential antithrombotic agent. Effects on human platelets in vitro. Federation Proceedings. 35: 807
• 10 Rao GH, White JG, Jachimowicz AA, Witkop CJ. 1976; An improved method for the extraction of endogenous platelet serotonin. Journal of Laboratory and Clinical Medicine 87: 129
• 11 Roba J, Bourgain R, Andries R, Claeys M, Van Opstal W, Lambelin G. 1976; Antagonism by suloctidil of arterial thrombus formation in rats. Thrombosis Research 9: 585
• 12 Saunders RN, Burns TS, Stelzer MR, Waskawic ER. 1977; The retired breeder rat as a new model for antiplatelet drug dicovery. Laboratory Animal Science 27: 151
• 13 Wu KK, Hoak JC. 1975; Increased platelet aggregates in patients with transient ischemic attacks. Stroke 6: 521